Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Cash from Financing Activities: 2020-2023

Historic Cash from Financing Activities for Candel Therapeutics (CADL) over the last 2 years, with Dec 2023 value amounting to -$121,000.

  • Candel Therapeutics' Cash from Financing Activities fell 436.11% to -$121,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $19.9 million, marking a year-over-year decrease of 78.26%. This contributed to the annual value of $94.3 million for FY2024, which is 78017.36% up from last year.
  • As of Q4 2023, Candel Therapeutics' Cash from Financing Activities stood at -$121,000, which was down 436.11% from $36,000 recorded in Q4 2022.
  • Over the past 5 years, Candel Therapeutics' Cash from Financing Activities peaked at $71.4 million during Q3 2021, and registered a low of -$121,000 during Q4 2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was $112,000 (2021), whereas its average is $13.1 million.
  • Per our database at Business Quant, Candel Therapeutics' Cash from Financing Activities spiked by 17,682.14% in 2022 and then slumped by 436.11% in 2023.
  • Candel Therapeutics' Cash from Financing Activities (Quarterly) stood at $29,000 in 2020, then reached $71.4 million in 2021, then slumped by 93.39% to $36,000 in 2022, then slumped by 436.11% to -$121,000 in 2023.
  • Its Cash from Financing Activities stands at -$121,000 for Q4 2023, versus $36,000 for Q4 2022 and $22,000 for Q2 2022.